Literature DB >> 19842664

Design, synthesis, and structure-activity relationship of indole-3-glyoxylamide libraries possessing highly potent activity in a cell line model of prion disease.

Mark J Thompson1, Vinciane Borsenberger, Jennifer C Louth, Katie E Judd, Beining Chen.   

Abstract

Transmissible spongiform encephalopathies (TSEs) are a family of invariably fatal neurodegenerative disorders for which no effective curative therapy currently exists. We report here the synthesis of a library of indole-3-glyoxylamides and their evaluation as potential antiprion agents. A number of compounds demonstrated submicromolar activity in a cell line model of prion disease together with a defined structure-activity relationship, permitting the design of more potent compounds that effected clearance of scrapie in the low nanomolar range. Thus, the indole-3-glyoxylamides described herein constitute ideal candidates to progress to further development as potential therapeutics for the family of human prion disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19842664     DOI: 10.1021/jm900920x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.

Authors:  B Michael Silber; Satish Rao; Kimberly L Fife; Alejandra Gallardo-Godoy; Adam R Renslo; Deepak K Dalvie; Kurt Giles; Yevgeniy Freyman; Manuel Elepano; Joel R Gever; Zhe Li; Matthew P Jacobson; Yong Huang; Leslie Z Benet; Stanley B Prusiner
Journal:  Pharm Res       Date:  2013-02-16       Impact factor: 4.200

Review 2.  Senescence suppressors: their practical importance in replicative lifespan extension in stem cells.

Authors:  Eun Seong Hwang
Journal:  Cell Mol Life Sci       Date:  2014-07-23       Impact factor: 9.261

3.  Melanin or a Melanin-Like Substance Interacts with the N-Terminal Portion of Prion Protein and Inhibits Abnormal Prion Protein Formation in Prion-Infected Cells.

Authors:  Taichi Hamanaka; Keiko Nishizawa; Yuji Sakasegawa; Ayumi Oguma; Kenta Teruya; Hiroshi Kurahashi; Hideyuki Hara; Suehiro Sakaguchi; Katsumi Doh-Ura
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

4.  Prion and Prion-like Diseases in Humans: Poster Abstracts.

Authors: 
Journal:  Prion       Date:  2013 Apr/May       Impact factor: 3.931

5.  2-Aminothiazoles as therapeutic leads for prion diseases.

Authors:  Alejandra Gallardo-Godoy; Joel Gever; Kimberly L Fife; B Michael Silber; Stanley B Prusiner; Adam R Renslo
Journal:  J Med Chem       Date:  2011-01-19       Impact factor: 7.446

6.  Inhibition of PrP(Sc) formation in scrapie infected N2a cells by 5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine derivatives.

Authors:  Fani Koukouli; Ioannis Paspaltsis; Evgenia Salta; Konstantinos Xanthopoulos; Eftychia N Koini; Theodora Calogeropoulou; Theodoros Sklaviadis
Journal:  Prion       Date:  2012-08-23       Impact factor: 3.931

7.  Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones.

Authors:  Yuji O Kamatari; Yosuke Hayano; Kei-ichi Yamaguchi; Junji Hosokawa-Muto; Kazuo Kuwata
Journal:  Protein Sci       Date:  2012-11-19       Impact factor: 6.725

8.  Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.

Authors:  B Michael Silber; Joel R Gever; Zhe Li; Alejandra Gallardo-Godoy; Adam R Renslo; Kartika Widjaja; John J Irwin; Satish Rao; Matthew P Jacobson; Sina Ghaemmaghami; Stanley B Prusiner
Journal:  Bioorg Med Chem       Date:  2013-09-18       Impact factor: 3.641

9.  Optimization of Arylamides as Novel, Potent and Brain-penetrant Antiprion Lead Compounds.

Authors:  Zhe Li; Satish Rao; Joel R Gever; Kartika Widjaja; Stanley B Prusiner; B Michael Silber
Journal:  ACS Med Chem Lett       Date:  2013-07-11       Impact factor: 4.345

10.  QSAR study of anti-prion activity of 2-aminothiazoles.

Authors:  Prasit Mandi; Chanin Nantasenamat; Kakanand Srungboonmee; Chartchalerm Isarankura-Na-Ayudhya; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2012-08-15       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.